Drugs / NordiFlex
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04633057 Comparator | Jan 2021 → Jul 2023 | pituitary deficiency | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NordiFlex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04633057 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Somatropin Injection” NCT04633057 ↗ |